

# Clinical trials of rivaroxaban 5mg

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 acute coronary syndrome

Trial	Treatments	Patients	Trials design and methods
<b>rivaroxaban 5mg vs placebo</b>			
<b>ATLAS ACS-TIMI 46 (5mg) , 2009</b> [NCT00402597] n=519/1160 follow-up: 6 months	rivaroxaban 5 mg twice daily versus placebo	recent ACS patients treated with aspirin alone (n=761) or aspirin plus clopidogrel (n=2730)	Parallel groups double blind 27 countries
<b>ATLAS ACS 2 - TIMI 51 (5mg) , 2011</b> [NCT00809965] n=5176/5176 follow-up: 13 months	rivaroxaban 5 mg twice daily in addition to standard care versus placebo	patients with a recent ACS	double blind 44 countries

More details and results :

- antithrombotics for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q24>
- anticoagulant for acute coronary syndrome in All ACS (including AMI) at <http://www.trialresultscenter.org/go-Q167>
- direct factor Xa inhibitors for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q345>
- antithrombotics for acute coronary syndrome in patients with a recent ACS at <http://www.trialresultscenter.org/go-Q387>
- direct oral anticoagulant (DAO) for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q480>

## References

### ATLAS ACS-TIMI 46 (5mg), 2009:

Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009 Jul 4;374:29-38 [19539361]

### ATLAS ACS 2 - TIMI 51 (5mg), 2011:

Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. N Engl J Med 2011 Nov 13; [22077192] 10.1056/NEJMoa1112277

Entry terms: rivaroxaban, Xarelto, BAY 59-7939,